U.S. markets close in 35 minutes
  • S&P 500

    3,665.34
    -27.89 (-0.76%)
     
  • Dow 30

    29,305.91
    -284.50 (-0.96%)
     
  • Nasdaq

    10,852.34
    -15.58 (-0.14%)
     
  • Russell 2000

    1,666.06
    -13.53 (-0.81%)
     
  • Crude Oil

    76.79
    -1.95 (-2.48%)
     
  • Gold

    1,635.20
    -20.40 (-1.23%)
     
  • Silver

    18.43
    -0.48 (-2.51%)
     
  • EUR/USD

    0.9618
    -0.0070 (-0.72%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • GBP/USD

    1.0694
    -0.0163 (-1.50%)
     
  • USD/JPY

    144.5930
    +1.2730 (+0.89%)
     
  • BTC-USD

    19,168.55
    +208.78 (+1.10%)
     
  • CMC Crypto 200

    440.40
    +7.30 (+1.68%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

·1 min read
Foghorn Therapeutics, Inc.
Foghorn Therapeutics, Inc.

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in upcoming investor conferences in September. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Morgan Stanley 20th Annual Global Healthcare Conference 
Monday, September 12, 2022, at 8:45 a.m. ET
Please find a link to the fireside chat here

H.C. Wainwright 24th Annual Global Investment Conference 
Tuesday, September 13, 2022, at 10:00 a.m. ET
Please find a link to the presentation here

A webcast of the fireside chat and presentation will be accessible under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will remain available for up to 90 days.

About Foghorn Therapeutics
Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media)
michael@scientpr.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com